Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

Published:2021-12 Issue:12 Volume:22 Page:1692-1704
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tawbi Hussein A,Forsyth Peter A,Hodi F Stephen,Algazi Alain P,Hamid Omid,Lao Christopher D,Moschos Stergios J,Atkins Michael B,Lewis Karl,Postow Michael A,Thomas Reena P,Glaspy John,Jang Sekwon,Khushalani Nikhil I,Pavlick Anna C,Ernstoff Marc S,Reardon David A,Kudchadkar Ragini,Tarhini Ahmad,Chung Caroline,Ritchings Corey,Durani Piyush,Askelson Margarita,Puzanov Igor,Margolin Kim A

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Prognostic factors for survival in melanoma patients with brain metastases;Davies;Cancer,2011

2. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study;Cagney;Neuro-oncol,2017

3. The biology of melanoma brain metastasis;Fidler;Cancer Metastasis Rev,1999

4. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases;Sperduto;J Clin Oncol,2012

5. Target therapies for melanoma brain metastases;Berghoff;Curr Treat Options Neurol,2017

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups;Computational and Structural Biotechnology Journal;2024-12

2. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

3. Progress in Immune Checkpoint Inhibitor for Melanoma Therapy;Hematology/Oncology Clinics of North America;2024-10

4. Perspective Chapter: Targeting the Myeloid Compartment – Innovative Immunotherapy Strategies for Malignant Brain Tumors;Advanced Concepts and Strategies in Central Nervous System Tumors [Working Title];2024-09-13

5. Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma‐associated leptomeningeal disease;Journal of the European Academy of Dermatology and Venereology;2024-09-12